Rod Cells News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Researchers used CRISPR-based genome editing to successfully restore vision in mice with retinitis pigmentosa, a major cause of blindness in humans.

We're delivering into the body. in addition, at meira, we've actually developed, over the last seven years, a totally new technology which allows us to, in the future, control how those genes delivered to the body are activated using pills. one of the six clinical trials taking place here is targeting an inherited eye condition called retinitis pigmentosa. it causes light—detecting cells in the retina to break down over time, causing a person to eventually lose vision. red are the rod cells and green are the cone cells, so they exist in this kind of mosaic. early results of using gene therap...

Started, one of the big issues was how do you get those genes into people? so we, and others, over the last five to ten years, have developed a new viral vector, and we're manufacturing that here to deliver the genes we're delivering into the body. in addition, at meira, we've actually developed, over the last seven years, a totally new technology which allows us to, in the future, control how those genes delivered to the body are activated using pills. one of the six clinical trials taking place here is targeting an inherited eye condition called retinitis pigmentosa. it causes light—detect...

Here to deliver the genes we're delivering into the body. in addition, at meira, we've actually developed, over the last seven years, a totally new technology which allows us to, in the future, control how those genes delivered to the body are activated using pills. one of the six clinical trials taking place here is targeting an inherited eye condition called retinitis pigmentosa. it causes light—detecting cells in the retina to break down over time, causing a person to eventually lose vision. red are the rod cells and green are the cone cells, so they exist in this kind of mosaic. early re...

Becoming incorrectly switched on, this treatment tries to turn it off — or vice versa. when the idea of gene therapy started, one of the big issues was, how do you get those genes into people? so we, and others, over the last five to ten years, have developed a new viral vector, and we're manufacturing that here to deliver the genes we're delivering into the body. in addition, at meira, we've actually developed, over the last seven years, a totally new technology which allows us to, in the future, control how those genes delivered to the body are activated using pills. one of the six clinica...